Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2002

View Archived Issues

New treatment option for ADHD available in the U.S.

First FDA-approved dual-component lipid modulator reaches market

RBx-7644: a new oxazolidinone presented by Ranbaxy at ICMASKO

Novel macrolides evaluated in vitro and in murine infection models at GSK and Pliva

KRX-101 cleared to enter South African phase II trial in HIV-associated nephropathy

Preclinical data support expanded preclinical program for HRC-102

Inspire reprioritizes its pipeline

MG-98 enters clinical trials in MDS and AML

Pozen's antimigraine product candidate noncarcinogenic in mice

Epimmune reschedules IND filing for lead HIV vaccine candidate

Antiarrhythmics and antidepressants discovered to be fungicidal

Sugen claims compounds that modulate protein kinases and phosphatases

Antibacterial oxazolidinones with potent and broad-spectrum activity

Patent covers new NK1 antagonists designed at Roche

Pyrrolopyrimidine-2,4-dione derivatives that selectively inhibit PDE5 identified

Adamantane-based P2X7 receptor antagonists discovered by AstraZeneca team

Byk Gulden synthesizes dual beta2-adrenoceptor agonist/PDE4 inhibitor compounds

Bicyclic cyclohexylamines with utility in Parkinson's disease described in patent

Compounds useful in hyperproliferative disorders claimed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...